Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

BSAVA’s CEO to leave organisation after 14 years
“(...)it’s been an honour to have played a part in supporting such a wonderful profession.” – Amanda Stranack, BSAVA CEO.
Amanda Stranack’s final day will be 30 April 2026.

The British Small Animal Veterinary Association (BSAVA) is to transition to a new chief executive officer (CEO), with Stacy Woodman sitting interim CEO.

Ms Woodman will support the organisation through the transition as Amanda Stranack prepares to leave after 14 years with BSAVA.

Amanda Stranack first joined the organisation in 2012 as head of congress, before becoming director of operations in 2016. She was appointed CEO in 2019, where she became closely involved with the organisation’s strategic development.

During Ms Stranack’s time as CEO, membership for BSAVA has increased to more than 10,000 members. She has also contributed to plans that will shape the organisation’s future.

Ms Stranack said: “I’m proud of what we’ve achieved together and grateful to the team, volunteers, partners and veterinary community who have supported our work. The dedication and expertise within the BSAVA have been inspiring and it’s been an honour to have played a part in supporting such a wonderful profession.”

Stacy Woodman will be stepping in as interim CEO before a permanent appointment is made.

Ms Woodman has been leading BSAVA’s Programme of Change, working closely with the Board and leadership team to shape a new business plan and strategy. BSAVA says that her expertise and organisational knowledge will provide ‘continuity’ during the transition.

The BSAVA has begun recruiting a permanent CEO, with a further update to follow in due course.

Stacy Woodman said: “I’m pleased to be stepping into the Interim CEO role and supporting the organisation through this next phase. Having worked closely with the Board and leadership team on the Programme of Change, I understand both the ambition and the realities behind the plan. The BSAVA has a capable team and a clear direction, and I’m looking forward to working together to deliver on what we’ve set out to achieve.”

Julian Hoad, BSAVA president, said: “Amanda’s contribution to the BSAVA over the past 14 years has been exceptional. She has led with professionalism, warmth and a deep commitment to the veterinary profession. From her early work as Head of Congress through to CEO, she has played a major role in shaping the BSAVA’s progress and helping position the Association for its next phase.

“We thank Amanda for everything she has given to the BSAVA and wish her well for the future. And as we move into that next phase, we are delighted to welcome Stacy as our Interim CEO.”

Image © BSAVA

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.